New Cancer Imaging Approach Could Enable Better Detection of Pancreatic Tumors

By Julie Grisham,

Wednesday, August 10, 2016

Three images of pancreas tumor

These images show a tumor that is being targeted with a new drug called 89Zr-DFO-5B1, which is designed to detect CA19.9, a protein that is elevated in more than 90% of pancreatic tumors as well as in some other cancers. Memorial Sloan Kettering was recently given permission from the FDA to conduct the first-ever clinical trial with this new drug in patients with pancreatic cancer. 

The left panel shows a thin slice of the tumor that has been stained with a dye that allows researchers to distinguish the different types of cells present. The middle panel is a heat map indicating the area in which the drug accumulated in the tumor tissue after it was injected into the mouse. The right panel shows the relative amount of the target protein to which the radiopharmaceutical was directed.

The drug being tested here is what’s called a radiopharmaceutical, a compound made of an antibody coupled to a radioactive atom that can be imaged with PET scans.

By comparing the middle and right panel, the researchers can confirm that 89Zr-DFO-5B1 is successfully going where it’s supposed to go in the body.

The drug was developed in the laboratory of MSK radiochemist Jason Lewis, in collaboration with the company MabVax Therapeutics Holdings.

Pancreatic Cancer Clinical Trials & Research
Through clinical trials, we’re studying new approaches to treating pancreatic cancer and coming closer to finding promising solutions.
Learn more


Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.